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Introduction
 Astrocytic tumors (astrocytomas) are the most common 
primary glial tumors of the central nervous system (CNS), 
and are classified according to a grading system developed 
by the World Health Organization (WHO), from low grade 
astrocytomas (diffuse astrocytoma, pilocytic astrocytoma) 
to high grade astrocytomas (anaplastic astrocytoma, 
glioblastoma) (Louis et al., 2007).
 Glioblastoma (GBM) is the most common primary 
malignant tumor of the CNS in adults, representing 50% 
of all gliomas and 20% of all solid intracranial lesions 
that undergo surgery. With a mean incidence of 3 per 
year per 100.000 persons (Mineo et al., 2002; Rainov et 
al., 2007), it ranks fourth among the causes of death due 
to cancer in the middle-aged population (Hiesiger et al., 
1993). Despite advances in the therapeutic management 
of GBM, prognosis remains poor and the median overall 
survival rate is <1 year. Several factors, such as age, 
performance status, radiotherapy, chemotherapy, quality of 
surgery, location and nature (de novo or secondary glioma) 
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Abstract
 Background: Astrocytic tumors, the most common primary glial tumors of the central nervous system, are 
classified from low to high grade according to the degree of anaplasia and presence of necrosis. Despite advances 
in therapeutic management of high grade astrocytic tumors, prognosis remains poor. In the present study, the 
frequency and prognostic significance of c-erb-B2 in astrocytic tumors was investigated. Materials and Methods: 
Records of 72 patients with low- and high-grade astrocytic tumors were evaluated. The expression of C-erbB-2 
was determined immunohistochemically and intensity was recorded as 0 to 3+. Tumors with weak staining (1+) 
or no staining (0) were considered Her-2 negative, while tumors with moderate (2+) and strong (3+) staining 
were considered Her-2 positive. Results: Of the 72 patients, 41 (56.9%) had glioblastoma (GBM), 10 (13.9%) 
had diffuse astrocytoma, 15 (20.8%) had anaplastic astrocytoma, 6 (8.3%) had pilocytic astrocytoma. C-erbB-2 
overexpression was detected in the tumor specimens of 17 patients (23.6%). Six (8.3%) tumors, all GBMs, 
exhibited strong staining, 2 (2.7%) specimens, both GBMs, exhibited moderate staining, and 9 specimens, 5 of 
them GBMs (12.5%), exhibited weak staining. No staining was observed in diffuse astrocytoma and pilocytic 
astrocytoma specimens. Median overall survival of patients with C-erbB-2 negative and C-erbB-2 positive tumors 
were 30 months (95%CI: 22.5-37.4 months) and 16.9 months (95%CI: 4.3-29.5 months), respectively (p=0.244). 
Conclusions: Although there was no difference in survival, C-erbB-2 overexpression was observed only in the 
GBM subtype. 
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of the tumor have been established as prognostic factors 
(Stummer et al., 2008; Gulati et al., 2011; 2012; Jakola 
et al., 2012). At the time of tumor recurrence, treatment 
options are limited and survival is short.
 Epidermal growth factor receptors (EGFR), 
transmembrane receptors located on the surface of 
epithelial cells, are crucial in the activation of subcellular 
signal transduction pathways controlling epithelial 
cell growth differentiation (Haapasala et al., 1996). 
Overexpression of EGFR has been shown to be a negative 
prognostic marker for survival in multiple cancer types, 
including breast, bladder, esophagus, cervix and ovarian 
carcinomas (Neal et al., 1985; Sainsbury et al., 1987; 
Ozawa et al., 1989; Pfeiffer et al., 1989; Bauknecht et 
al., 1989). EGFR targeted therapies have been introduced 
in carcinomas of the lung and colon (Wan den Eynde et 
al., 2011). In astrocytic tumors, however, the prognostic 
and diagnostic role of EGFR has shown divergent results 
(Pigott et al., 1993; Koka et al., 2003; Potti et al., 2004; 
Haynik et al., 2007).
 C-erb-B2 (also known as Her-2/neu) is a member 
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of ErbB family, located on chromosome region 17q12, 
encoding for a 185 kD transmembrane glycoprotein 
with intracellular tyrosine kinase activity. The c-erb-B2 
receptor belongs to the family of EGFRs.
 In this study, we investigated the frequency and 
prognostic significance of c-erb-B2 as well as the effects 
of tumor characteristics on survival in a small group of 
patients with low- and high-grade astrocytic tumors.
Materials and Methods
 After the study was approved by the Institutional 
Review Board of Baskent University, the records of 
72 patients with low- and high-grade astrocytic tumors 
diagnosed, followed and treated at the Medical Oncology 
Department of Adana Hospital of Baskent University, 
between 2006-2011, were investigated. Gender, age, type 
of operation, treatment modality, and tumor characteristics 
as location, grade, histological subtype, Ki-67 levels and 
C-erbB-2 status were evaluated retrospectively. The vital 
status of each patient (alive, dead and if dead the death 
date) was noted or inquired by phone, when required.
 Tumor specimens were obtained from the pathology 
laboratory archives and prepared for immunohistochemistry. 
Four micron thick sections cut from the selected paraffin 
blocks were immunohistochemically stained by the same 
pathologist with polyclonal rabbit anti-human c-erbB-2 
oncoprotein (Ref: A0485, Lot: 00076694, DAKO, 
Carpinteria, Ca, USA) in Dako Autostainer Link 48. 
Brown-red coloration in tumor cytoplasmic membrane 
by light microscopy was considered c-erbB-2 positive. 
If there was no staining, it was considered as 0. Pale 
and partial membranous staining in less than 10% of 
tumor cells was recorded as weak staining (1+), pale 
and complete staining in more than 10% of tumor cells 
was recorded as moderate staining (2+) and strong and 
complete staining in more than 10% of tumor cells was 
recorded as strong (3+).
 Tumors with weak staining (1+) or no staining (0) were 
considered to be C-erbB-2 negative, while tumors with 
moderate (2+) and strong (3+) staining were considered 
to be C-erbB-2 positive.
 Data analysis was performed using Statistical Package 
for Social Sciences (SPSS) for Windows version 11.5 
(SPSS Inc., Chicago, IL, USA) software. Continuous 
variables were expressed as mean±standard deviation or 
median (minimum-maximum), while categorical variables 
were expressed as percentages (%) and numbers.
 We evaluated the effects of factors such as gender, 
type of operation, tumor location, histological subtype, 
C-erbB-2 status, and treatment modality on overall 
survival by using log rank test with Kaplan Meier survival 
analysis. Univariate and multivariate analyses were 
performed using the Cox proportional hazards regression 
model. A p value<0.05 was considered to be statistically 
significant.
Results 
 Between 2006 and 2011, 72 subjects (32 females, 40 
males) with a biopsy-proven diagnosis of an astrocytic 
tumor were identified. The mean age was 48.6±17.7 years 
(range, 12-81 years). The median follow-up period was 
12 months (range, 1-75 months).
 Among 72 patients, 41 (56.9%) were diagnosed 
as having GBM (grade IV), 15 (20.8%) as anaplastic 
astrocytoma (grade III), 10 (13.9%) as diffuse astrocytoma 
(grade II), and 6 (8.3%) as pilocytic astrocytoma (grade 
I). While 36 of 41 GBM patients had de-novo (primary) 
GBM, 5 patients had secondary GBM, i.e. transformation 
of low-grade glioma.
 The neoplasm was located in the left cerebral 
hemisphere in 28 patients (12 in the frontal lobe, 6 in the 
parietal lobe, 6 in the temporal lobe, 3 in the occipital 
lobe and 4 in the cerebellar region). Of those located in 
the right hemisphere (n=44), 18 were in the temporal lobe, 
13 were in the frontal lobe, 9 were in the parietal lobe and 
1 was in the occipital lobe. Gross total tumor resection 
was achieved in 12 (16.7%) patients, subtotal resection 
was achieved in 42 (58.3%) patients, and decompression 
was achieved in 10 (13.9%) patients. Only biopsies were 
taken in 8 (11.1%) patients.
 While 19 (26.4%) patients had received no treatment, 
21 (29.2%) patients had received radiotherapy, 7 (9.7%) 
patients had received chemoradiotherapy, 17 (23.6%) 
patients had received chemotherapy (temozolomide) 
followed by chemoradiotherapy, and 8 (11.1%) patients 
had received chemotherapy followed by radiotherapy. 
Forty-eight patients had died by the end of follow-up 
period. Demographic and clinical characteristics of the 
patients are shown in Table 1.
 Location of the tumor was significantly associated with 
Table 1. Demographic and Clinical Characteristics 
of Patients
Variables n=72
 Age (Years) Mean±SD (min-max) 48.6±17.7 (12-81)
Gender, n (%) Male 40 (55.6)
 Female 32 (44.4)
Pathology, n (%) GBM 41 (56.9)
 Anaplastic astrocytoma 15 (20.8)
 Diffuse astrocytoma 10 (13.9)
 Pilocytic astrocytoma 6   (8.3)
Localization, n (%) Frontal 25 (34.7)
 Occipital 4   (5.6)
 Parietal 15 (20.8)
 Cerebellar 4   (5.6)
 Temporal 24 (33.3)
Her-2 Staining, n (%) 0 55 (76.4)
 (+1) 9 (12.5)
 (+2) 2   (2.8)
 (+3) 6   (8.3)
Type of Operation, n (%) Subtotal resection 42 (58.3)
 Gross total tumor resection 12 (16.7)
 Only biopsies 8 (11.1)
 Decompression 10 (13.9)
Treatment, n (%) 
 No treatment 19 (26.4)
 Only radiotherapy 21 (29.2)
 Only chemoradiotherapy 7   (9.7)
 Chemoradiotherapy plus temozolomide 17 (23.6)
 Radiotherapy plus temozolomide 8 (11.1)
 Progression, n (%) 22 (30.6)
 Dead, n (%) 48 (66.7)
 Follow-up period (months), median (min-max) 12 (1-75)
*SD: Standard deviation, GBM: Glioblastoma
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survival (p=0.049). The median overall survival for frontal 
lobe tumors and temporal lobe tumors were 30.2 and 31.9 
months, while the median overall survival in occipital 
lobe tumors and parietal lobe tumors were 15.7 and 15.6 
months, respectively. Median overall survival was 17.4 
months for GBM patients, 28.1 months for anaplastic 
astrocytomas, and 55.1 months for diffuse astrocytomas 
(p<0.001).
 For the histological subtype and grade multivariate 
analysis could not be performed as there was a multiple 
relation problem. The histological subtype of cases with 
Grade I tumor was pilocytic astrocytoma, and all the cases 
were alive, while the histological subtype of cases with 
Grade IV tumor was GBM, and all the cases were dead.
 C-erbB-2 overexpression was detected in the tumor 
specimens of 17 patients (23.6%), 13 patients with 
GBM and 4 patients with anaplastic astrocytoma. Six 
tumors (8.3%), all GBMs, showed strong (3+) staining, 
2 specimens (2.7%), both GBMs, had moderate staining 
(2+) and 9 specimens, 5 of them GBMs (12.5%), exhibited 
weak staining (1+). All the GBM specimens that showed 
staining were primary GBM. No staining was observed in 
diffuse astrocytoma and pilocytic astrocytoma specimens. 
The degree of c-erb-B2 positivity is shown in Table 2.
 Median overall survival of patients with C-erbB-2 
negative and C-erbB-2 positive tumors were 30 months 
(95%CI: 22.5-37.4 months) and 16.9 months (95%CI: 
4.3-29.5 months), respectively (p=0.244). Survival curves 
are shown in Figure 1.
 C-erbB-2 was positive in 8 GBM patients (19.5%) 
and negative in 33 (80.5%) patients. Survival difference 
between the 2 groups was not statistically significant 
(p=0.152).
Discussion
The present study performed in a small sample of 
low- and high-grade astrocytomas, failed to identify a 
statistically significant difference in terms of survival 
between patients with C-erbB-2 positive and C-erbB-2 
negative tumors, although the median overall survival 
in these two groups of patients was 30 and 16.9 months. 
Astrocytic tumors, particularly anaplastic astrocytomas 
and GBM, face a poor prognosis despite major efforts to 
improve radiation therapy, chemotherapy, and surgery. 
While median survival for patients with anaplastic 
astrocytoma was reported to be between 3 and 5 years, 
median survival for patients with GBM was 12 to18 
months, with the best available treatment. Although 
several prognostic factors such as age, performance 
status, quality of surgery, chemotherapy, radiotherapy 
and location of the tumor, have been proposed, there is 
a need for reliable prognostic indicators in patients with 
brain tumors.
Overexpression of C-erbB-2 has been established as an 
indicator of poor prognosis in a number of malignancies 
other than the CNS tumors. In the literature, the rate of 
C-erbB-2 overexpression is >20% in gastric cancers, 33% 
in gastroesophageal junction cancers (Albarello et al., 
2011) and 31% in non-small cell lung cancers (Hirsch et 
al., 2012). Similarly, C-erbB-2 is overexpressed in 18-20% 
of invasive breast cancers (Slamon et al., 1987; Yaziji et 
al., 2004). However, the rates of C-erbB-2 overexpression 
in astrocytic tumors vary in the literature. While Reszeć 
et al. (2011) observed a C-erbB-2 overexpression rate 
of 47.1% in diffuse astrocytoma, 40% in anaplastic 
astrocytoma and 34.8% in GBM, Torp et al. (2007) 
demonstrated C-erbB-2 overexpression in 9 of 21 GBM 
patients (43%). Haynik et al. (2007), in their study on 49 
GBM patients did not show C-erbB-2 overexpression in 
any of these patients. Haapasalo et al. (1996) screened 
immunuhistochemically c-erb-B2 protein expression in 
94 astrocytic grade 1-4 neoplasm of the brain. Only two 
Table 2. Degree of C-erb-B2 Positivity According to 
Histopathology
 GBM Anaplastyic Diffuse Oligo- Pilosytic
  Astrocytoma Astrocytoma Astrocytoma Astrocytoma
c-erb-B2 stain
n=72 41 15 6 4 6
   Negative 28 11 6 4 6
   (1+) positive 5 4 - - -
   (2+) positive 2 - - - -
   (3+) positive 6 - - - -
GBM: Glioblastoma
Table 3. Published Studies on Her-2 Overexpression and Prognostic Significance in Astrocytic Tumors
Reference n Tumor type  Her-2 positivity rate Her-2 Prognostic
    negativity rate significance
Potti et al.3 347 Astrocytic Tumor GBM 15.6 % 84.4 % Yes (p=0.01)
   Diffuse Astrocytoma 6.0 % 94.0 % 
   Anaplastic Astrocytoma 8.0 % 92.0 % 
Koka et al. 149 GBM  15.4 % 84.6 % Yes (p<0.01)
Denise et al.  44 GBM  0 % 100 % No
Resjec et al.  65 Astrocytic Tumor GBM 82.6 % 17.4 % Not evaluated
   Diffuse Astrocytoma 88.3 % 11.7 % 
   Anaplastic Astrocytoma 88.0 % 12.0 % 
Pigott JR et al.  88 GBM  19.3 % 80.7 % No
GBM: Glioblastoma
Figure 1. Cumulative Survival Curves for Patients with 
c-erbB-2 Negative and Positive Tumors 
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anaplastic (grade 3) astrocytomas and one GBM (grade 
4) showed overexpression, interestingly, no amplification 
of the c-erb-B2 gene was observed by fluorescence in 
situ hybridization (FISH). In another study, Potti et al. 
(2004) reported C-erbB-2 overexpression in 36 of 347 
patients with primary malignant brain tumors (10.4%). 
In this study, 23 (64%) of 36 patients with C-erbB-2 
overexpression were patients with GBM. In our study, 
C-erbB-2 positivity (2+ and 3+ staining) was observed in 
11% of patients with low and high-grade astrocytomas. 
It was not surprising to find out that all tumors with 
Her-2 overexpression were GBMs, 19.5% of patients 
with GBM showed C-erbB-2 overexpression. C-erbB-2 
overexpression was not identified in any of the other 
astrocytomas.
Similarly, conflicting findings exist regarding the 
association between prognosis and C-erbB-2 expression. 
Mineo et al. (2002) showed that survival time was 
significantly longer when C-erbB-2 expression was low 
(p=0.04). Koka et al. (2003) in their study, revealed that 
C-erbB-2 overexpression significantly increased the odds 
of early mortality, and stated that C-erbB-2 overexpression 
may be a poor prognostic marker in patients with GBM. 
In another study, Potti et al. (2004) showed that C-erbB-2 
overexpression predicts increased mortality. Published 
studies on C-erbB-2 overexpression and prognostic 
significance in astrocytic tumors are shown in Table 3.
In our study, there was no significant difference 
between the two groups with C-erbB-2 negative (30 
months) and C-erbB-2 positive tumors (16.9 months) in 
terms of median overall survival (p=0.244). Although the 
difference between the two groups is clinically significant, 
the small sample size of our study limited our ability to 
detect a statistically significant difference.
Previous studies have demonstrated a variety of 
possible clinical and molecular prognostic indicators, 
but results have not been consistent. Gehan et al. (1997) 
showed that while young age, radiotherapy, chemotherapy 
and encapsulated tumor were favorable prognostic factors, 
parietal location was an unfavorable prognostic factor. In 
another study, Potti et al. (2004) demonstrated that tumor 
location (occipital, parietal), tumor histology (GBM), and 
presenting symptoms (nausea/vomiting) were related to 
poor prognosis in patients with primary malignant brain 
tumors. Similar to the literature, our findings suggest that 
tumor location (occipital and parietal) and tumor histology 
(GBM) are related to poor prognosis.
This retrospective study has limitations typical of 
immunohistochemical approaches, including limited 
technical reproducibility and subjective interpretation. 
The limited sample size is another important limitation.
Thus far, studies investigating the prognostic value 
of C-erbB-2 overexpression in human astrocytic tumors 
have produced mixed findings. In our study, although there 
was no difference in survival, C-erbB-2 overexpression 
was observed only in the GBM subtype. Large studies are 
necessary to fully clarify the prognostic role of C-erbB-2 
in human astrocytic tumors.
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